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Dear Editor 
Please find below the details regarding the revisions made to the manuscript: 
 
Ms. Ref. No.:  JPBA-D-13-01131 
Submitted Title: "Development and validation of a liquid chromatography-tandem mass 
spectrometric method to profile urinary cortisol metabolism" 
New title :" A comprehensive study for the validation of a LC-MS/MS method for the 
determination of free and total forms of urinary cortisol and its metabolites" 
Journal of Pharmaceutical and Biomedical Analysis 
 
addressed by the referees. 
 
Changes and corrections in the manuscript are highlighted in yellow.  
Below we reported the comments to each point raised by the referees 
  
 
- 1. In the title, the concept of "evaluation of cortisol metabolites with LC-MS/MS" is not good to 
explain what it has been done.  Please reconsider the title to emphasize your technical 
achievement. 
Authors answer : We changed the title into "A comprehensive study for the validation of a LC-
MS/MS method for the determination of free and total forms of urinary cortisol metabolism" 
 
- 2. In the abstract, the extraction recoveries should be mentioned along with results from free and 
total fractions. 
 
Authors answer :  Extraction recoveries and preliminary results on PCOS patients were mentioned 
in the abstract 
 
- 3. In the experimental, the glucuronide conjugates should be also contained in the sample 
preparation for free fraction.  Besides, concentrations of free and total fractions should be 
compared. 
 
Authors answer: The referees observation is not clear: urine samples for free fraction 
determination contain glucuronide conjugates. The latter are washed away (NH4OH and H2O-
MeOH washings) during the SPE purification of the urine for free fraction determination. The 
determination of free and total analytes are then made in two separated steps and samples. 
Glucuronides are about 99% of the total content of urinary glucocorticoids, thus the concentrations 
range are quite different. This difference is well know, in particular regarding the tetrahydro form, 
and it is quite evident from the results reported in the tables. However, we added a sentence at the 
end of section 3.6 to stress this aspect.  
 
- 4. Although the authors evaluated the dilution effects, the analyte-free urine could be conducted 
to establish the comprehensive analytical protocol.  The urinary cortisol and its metabolites can be 
easily removed by charcoal-stripping and Oasis HLB SPE purifications. 
 
Authors answer : As described in section 3.4, we carried out experiments also using analyte-free 
Response to Reviewers
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urine obtained by charcoal treatment, among the others. We used Oasisi HLB purification too, 
with and without a previous charcoal treatment. Using all those matrices to build calibration 
curves for the analytes under investigations provided beautiful curves, very close to the solvent 
calibration curves, but they proved to be not suitable in reproducing the urine matrix and the 
related effects on some compounds. That’s why we came to dilution evaluation. All of the above is 
described in details in section 3.4. 
 
- 5. Did you synthesize a deuterated cortisol in this study?  If not, a sentence "Deuterated cortisol 
was easily prepared ~" is not necessary. 
 
Authors answer :  Deuterated cortisol was prepared in our lab, following a reported procedure. 
That is claimed at line 108 in the Experimental. We stressed this aspect adding "in our lab" at line 
116 and 281 (in yellow in the revised manuscript text) 
 
 
- 6. A representative chromatogram obtained from the used blank urine should be also presented in 
Figure 2. 
 
Authors answer :  The blank urine we used for the calibration curves was a pool of urines sample, 
thus not so blank, as indicated in the text. We don’t see which improvement to the manuscript can 
provide the chromatogram of that urine, as it resembles to a typical urine sample. Anyway, if the 
editor considers it essential, there is no problem to provide the chromatogram. 
 
- 7. The efficiency of hydrolysis was mentioned in the results section.  How did you evaluate the 
efficiency?  Did you use the reference standards of conjugates of all analytes?  Please explain in  
details in the experimental section. 
 
Authors answer : The efficiency of conjugates enzymatic hydrolysis was evaluated following the 
approach reported in ref 26 and 27. Samples coming from the same pool of urines were hydrolyzed 
using different amount of enzyme and for different incubation periods, as reported in the Results 
section. When the concentration of the free forms reached a plateau, efficiency was assumed to be 
100%.   
We added a sentence explaining how we evaluated the efficiency in section 2.3.2 in the 
Experimental. 
 
- 8. Figure captions should be revised to explain in brief. 
Authors answer: captions of figures where changed as follows (yellow in body text): 
 
Figure 1 : Structures of cortisol and its metabolites. The enzymes involved in conversion of 
cortisol into cortisone and the corresponding tetrahydrometabolites are reported 
 
Figure 2 : Typical LC-MS/MS chromatographic profiles for the determination of cortisol and its 
metabolites in an urine sample. The chromatographic traces for the MS/MS transition of each 
compound (see Table 1 for conditions) are superimposed. It is worth notice the separation of THF 
from A-THF peak, as the two compounds share the same transition. 
 
Figure 3 : Dilution plot of E. Plateau level for the concentration of E was obtained using a 0.1 or 
less dilution factor, indicating that a ten-fold or more dilution is necessary to eliminate the matrix 
effects for E. 
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- 9. In line 408, "epatic" must be corrected. 
Authors answer: corrected 
 
- 10. In conclusion, the quantitative results from the method validation should be omitted. 
Authors answer: corrected 
 
 
- 11. In the references, there are many typo including abbreviation of journal name (ref. 6, 8, 12 
and 18) and authors' name (ref. 16). 
Authors answer: References were checked and corrected when necessary. 
 
 
- 12. In table 1, "transition" should be changed to "transition ion (m/z)". 
Authors answer: corrected. 
 
 
13. Table 3 and 4 should be merged. 
14. Table 6 and 7 should be merged as well. 
 
Authors answer: Tables 3 and 4 were merged into the new table 3, and table 6 and 7 were merged 
in the new table 5. 
 
 
15. In Graphical Abstract, the analytical scheme is too much general.  It would be better to 
describe cortisol metabolism associate with the results obtained from the PCOS. 
Authors answer: we changed the graphical abstract to stress more the potential of a complete 
cortisol metabolism profile to assess 11-HSD1 and 2 activity. We did not stress the association 
with the results obtained from PCOS samples, as those results are still preliminary and more 
samples should be examined to confirm them.  
 
 
We hope that the comments are clear and these revisions meet the Journal of Pharmaceutical and 
Biomedical Analysis requirements for publication. 
 
 
     Yours sincerely 
    Dr. Angela Cuzzola 
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Abstract 22 
Several pathological conditions can be related to the alteration of the urinary levels of 23 
cortisol (F) and its metabolites. The determination of each of them in the free and free 24 
plus conjugated form can provide a deeper insight into the impaired activity of the 25 
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 2 
cortisol metabolism enzymes, thus improving the diagnosis protocol currently based 26 
only on the determination of total amount of urinary cortisol metabolites. 27 
In that view, an LC-MS/MS method for the determination of the free and total amount 28 
of urinary F, cortisone (E), tetrahydrocortisol (THF), allo-tetrahydrocortisol (A-THF) 29 
and tetrahydrocortisone (THE) was thus developed and validated. Deconjugation of 30 
glucocorticoids was carried out by enzymatic hydrolysis. Analytes were extracted by 31 
solid phase extraction, separated by liquid chromatography and analyzed via electro-32 
spray ionization (negative ion mode) triple-quadrupole mass spectrometry in the 33 
selected reaction monitoring mode using a stable isotope-labeled internal standard. 34 
Baseline separation for all compounds, in particular the two stereoisomers A-THF and 35 
THF, was obtained. Matrix effects, not reported so far, were observed and minimized 36 
for the determination of urinary free E and THE. Validated range was 0.5–1000 ng/mL 37 
for A-THF and THF, 5–800 ng/mL for E and THE and 1–1000 ng/mL for F, with R2 38 
values greater than 0.9981. The LOD and LOQ of the described method ranged from 39 
0.1 to 3.0 ng/mL, while the extraction recoveries resulted close to 100%  for all the 40 
glucocorticoids determined. Precision and accuracy were well within ±10%. As 41 
suggested by the results obtained in the preliminary study on polycystic ovary syndrome 42 
(PCOS) urine samples, the method can be used to support clinical diagnosis of 43 
pathologies related to cortisol metabolism. In fact, levels of free and total 44 
glucocorticoids in control subjects were in agreement with previously reported data, as 45 
well as free and total A-THF/THF ratio in PCOS patients. Conversely, in the latter free 46 
F/E and A-THF + THF/THE ratios were lower than in control subjects (P<0.01), 47 
suggesting a possible alteration of 11-HSD1 and 11-HSD2 activity, to be further 48 
investigated. 49 
 50 
Keywords Cortisol Metabolites Urine LC-MS PCOS  51 
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 52 
1. Introduction 53 
Among glucocorticoids, cortisol (F) and its metabolites (Fig. 1) play different roles in 54 
human physiology and several pathological conditions [1,2]. Cortisol deficiency has 55 
been reported in patients with Addison’s syndrome leading to hypotension, while excess 56 
cortisol is observed in Cushing’s syndrome and determined by the onset of hypertension 57 
[3].
 
Altered metabolism of cortisol is also responsible for the apparent mineralocorticoid 58 
excess (AME) syndrome, congenital adrenal hyperplasia and adrenal insufficiency [4]. 59 
Recent evidences suggest that obesity, insulin resistance, hypertension, polycystic ovary 60 
syndrome [5] and hyperthyroidism [6] may also be related to this alteration. These and 61 
other disorders can be detected by monitoring the interconversion of cortisol and 62 
cortisone (E) and the related metabolites [7,8], in which several enzymes are involved. 63 
In the kidney and colon, 11-hydroxysteroid dehydrogenase type 2 (11-HSD2) 64 
inactivates cortisol to cortisone, while in the liver and adipose tissue, cortisol is 65 
regenerated from cortisone by 11-hydroxy steroid dehydrogenase type 1 (11-HSD1) 66 
[9]. Moreover, in the liver, the A-ring reductases (5, 5and 3 reductase) convert 67 
cortisol and cortisone to their tetrahydrometabolites, allo-tetrahydrocortisol (A-THF), 68 
tetrahydrocortisol (THF) and tetrahydrocortisone (THE) [10]. 69 
Congenital or acquired defects in the enzymes involved in the metabolism of cortisol 70 
induce alterations of the level of cortisol and its derivatives, leading to the consequent 71 
diseases cited above. Glucocorticoids are largely present in urine as conjugates 72 
derivatives [11]. The diagnosis is generally based on the determination of the total 73 
amount of urinary glucocorticoids, expressed as F/E, (A-THF + THF/THE) or A-74 
THF/THF ratios. However, the evaluation of the amount of the free forms can provide 75 
further information [2,9,12] and a deeper insight into the activity of the enzymes 76 
 4 
involved in the metabolism of cortisol (for instance 11-HSD2 [13] or 5-reductase 77 
[2]), thus affording a more accurate diagnosis of the related pathologies.  78 
Several analytical methods have been developed for the determination of cortisol and its 79 
metabolites by GC–MS based techniques [14,15], but they involve time-consuming 80 
derivatization steps due to the low volatilities of corticosteroids. In recent, LC-MS 81 
methods have been applied to the analysis of corticosteroids in biological fluids, but 82 
very few of them address the determination of F, E, THE, THF and A-THF all at once. 83 
In particular, to the best of our knowledge, only two papers [16,17], reported the 84 
separation of the two isomers THF and A-THF without chemical derivatization [18], 85 
that otherwise are determined together as THF + A-THF [12],
 
thus without providing 86 
any information regarding the 5 and -reductase activity.  87 
In that view, in our previous paper [16]
 
we compared the application of hyphenated MS 88 
techniques for the simultaneous measurement of free glucocorticoids, LC/MS resulting 89 
the most suitable for the task. Starting from there, here we report a comprehensive 90 
development study, with particular regard to matrix effects, and the validation of a 91 
method for the determination of free and total urinary F, E, THE, THF and A-THF. The 92 
method, that comprises solid phase extraction (SPE) and LC-MS/MS quantification, 93 
was developed within our project on the possible correlation between the levels of those 94 
compounds (free and conjugated form) and the clinical diagnosis of related pathologies. 95 
In particular, here we also report a preliminary application of the developed protocol to 96 
urines coming from polycystic ovary syndrome (PCOS) patients. 97 
 98 
*** Figure 1 here *** 99 
Fig. 1. Structures of cortisol and its metabolites. The enzymes involved in the 100 
conversion of cortisol into cortisone and the corresponding tetrahydrometabolites are 101 
reported 102 
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 103 
2. Experimental 104 
 105 
2.1 Reagents and chemicals 106 
All chemicals used (methanol, water and formic acid) were HPLC grade from Carlo 107 
Erba Reagenti S.p.A. (Rodano, MI, Italy). 5-Pregnan-3,11,17,21-tetrol-20-one 108 
(tetrahydrocortisol, THF, MW=366), 5-Pregnan-3,11,17,21-tetrol-20-one (allo-109 
tetrahydrocortisol, A-THF, MW=366) were purchased from Steraloids, Inc. (Newport, 110 
RI, USA); 5-Pregnan-3,17,21-triol-11,20-dione (tetrahydrocortisone, THE, 111 
MW=364), Pregn-4-en-11,17,21-triol-3,20-dione (cortisol, F, MW=362),  Pregn-4-112 
en-17,21-diol-3,11,20-trione (cortisone, E, MW=360), -glucuronidase by Helix 113 
Pomatia type H-1 (arylsulfatase ≥10000 U/g solid) were from Sigma–Aldrich 114 
Corporation (St. Louis, MO, USA). Pregn-4-en-9,11,19,19-
2
H-11,17,21-triol-3,20-115 
dione (cortisol-d4, Fd4, MW=366) was prepared in our lab according to a reported 116 
procedure [19].
 
SPE was carried on Oasis HLB SPE cartdriges (20 mL, 30 mg; Waters) 117 
with a Supelco extraction vacuum manifold. 118 
The activity of Helix Pomatia sample was evaluated following the rate of hydrolysis of 119 
4-nitrophenyl-β-D-glucuronide by UV, according to the procedure reported by Cichna 120 
[20]. The -glucuronidase activity resulted 570 U/g.121 
 122 
2.2 Calibrators and quality control samples 123 
 124 
Original stock solutions of each compound (1 mg/mL in MeOH) were stored at -20°C 125 
up to 6 months without any changes and brought to room temperature prior to use. 126 
Standard solutions of the analytes were prepared by diluting original stock solutions 127 
with MeOH. Cortisol-d4 (Fd4) were used as internal standard (IS). Solvent based 128 
standard calibration curves were constructed by using neat solutions obtained by 129 
 6 
dilution with H2O (50:50) of the standard methanolic solutions, in the way of obtaining 130 
a range of concentration 0.5-1000 ng/mL containing the IS at 50 ng/mL.  131 
A pool of 24h urine collections, provided by 25 healthy volunteers, was used as 132 
reference matrix for matrix based calibration curves. The latter were constructed by 133 
spiking aliquots of the pool of reference urine (2 mL) with standard solutions (100 L), 134 
in the way of obtaining a range of concentration 0.5-1000 ng/mL in the sample, before 135 
injection, containing the IS at 50 ng/mL. A further urine aliquot spiked only with 50 L 136 
of standard solution of IS (1 g/mL in MeOH) was used as blank. 137 
Quality control (QC) working solutions in MeOH at concentration of 150, 1500, 4500 138 
ng/mL of each analyte, containing 500 ng/mL of IS, were prepared by dilution of stock 139 
solutions. All matrix based calibration standards and QC samples were extracted and 140 
analyzed in the same manner as the unknown samples. 141 
For the evaluation of recovery and matrix effect three sets of samples were analyzed: 142 
1) QC standard solutions in neat solvent obtained from QC working solution by dilution 143 
1 to 10 with MeOH-H2O (50:50, v/v). 144 
2) Pre-spiked samples: QC working solutions (100 L) were added to three aliquots (2 145 
mL) of the urine pool and then extracted by SPE as described above. 100 L of the 146 
eluate was concentrated under flow nitrogen at 35°C and the residue was reconstituted 147 
in 200 L of MeOH-H2O (50:50, v/v). An aliquot of urine spiked with 50 L of the 148 
methanolic standard solution of IS (1 g/mL) was used as blank. 149 
3) Post-spiked samples: three aliquots of 2 mL of urine pool were extracted by SPE as 150 
described above. 100 L of the eluates were concentrated under flow nitrogen at 35°C 151 
and the residues were reconstituted in 20 L of the 150, 1500 and 4500 ng/mL QC 152 
working solutions, 80 L of MeOH and 100 L of H2O to provide the three QC samples 153 
with a 15, 150, 450 ng/mL final concentration after spiking, respectively. The residue 154 
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from a fourth aliquot was reconstituted in 10 L of the methanolic standard solution of 155 
IS (1 g/mL), 90 L of MeOH and 100 L of H2O, and used as blank. 156 
 157 
 158 
2.3 Sample preparation 159 
 160 
2.3.1 Determination of unconjungated glucocorticoids 161 
50 L of methanolic standard solution of IS (1 g/mL) was added to urine sample (2 162 
mL) previously centrifuged at 2000 g for 30 min. Each sample was loaded onto an Oasis 163 
HLB SPE cartdrige preconditioned with 1 mL of MeOH and followed by 1 mL of H2O. 164 
The loaded cartdrige was subsequently washed with 1 mL of 10% MeOH and 0.5 mL of 165 
2% NH4OH in 40% MeOH, and then glucocorticoids were eluted with 0.5 mL of 166 
MeOH. For LC-MS analysis, 100 L of eluate was diluted to 200 L with H2O. 167 
 168 
2.3.2 Determination of total (free plus conjugated) glucocorticoids 169 
Enzymatic hydrolysis conditions were optimized carrying out various experiments using 170 
different concentration of the enzyme and incubation periods, following the release of 171 
the unconjugated form by LC-MS/MS determination. When the concentration of the 172 
free forms reached a plateau, efficiency was assumed to be 100%.  173 
Deconjugation of glucocorticoids was carried out by enzymatic hydrolysis on 125 L of 174 
urine sample with 50 L of Helix Pomatia solution (-glucuronidase activity 40.5 U/mL 175 
in H2O) in 200 L of sodium acetate buffer (pH 5.1;0.5 M) for 4h at 55°C. The reaction 176 
mixture was then diluted to 1 mL  with H2O and spiked with 25 L of standard solution 177 
of IS (20 g/mL). The resulting solution was extracted by SPE as described above. For 178 
LC-MS analysis, 100 L of eluate (0.5 mL) was diluted 1 to 20 with MeOH-H2O (50:50 179 
v/v). 180 
 181 
2.4 Instrumentation and chromatographic conditions 182 
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 183 
An Applied Biosystems-MDS Sciex API 4000 triple-quadrupole mass spectrometer 184 
(Concord, Ont., Canada), equipped with Turbo-V IonSpray (TIS) source and interfaced 185 
to Perkin-Elmer Series 200 Micro High pressure mixing pump and a Series 200 186 
Autosampler (Perkin-Elmer, Boston, MA, USA), was used for LC/MS/MS analysis. 187 
The analytes were separated on a Restek Allure Biphenyl column (50   2.1 mm, 3 m) 188 
(Bellefonte, PA, USA) using as mobile phase MeOH and H2O with 0.1% of formic acid 189 
and flow-rate at 0.3 mL/min. Separation was achieved under the following 190 
chromatographic conditions: 48% MeOH for 13.5 min then increased to 52% MeOH in 191 
0.1 min and maintained for 4.4 min. Column equilibration time was 1.5 min. The 192 
temperature of the chromatographic column was maintained at 30°C. Injection volume 193 
was 20 L. We verified that injection of samples in pure methanol altered the 194 
chromatographic performances. Thus all the samples were injected as MeOH:H2O 195 
50:50 mixture, that substantially are the starting chromatographic conditions.  196 
Quantitation was performed using Selected Reaction Monitoring (SRM) in negative ion 197 
mode with a dwell time of 200 ms. The Applied Biosystems Analyst software 198 
―Quantitative Optimization‖ wizard was used to discern the optimal parameters by flow 199 
injection analysis. The turboionspray temperature was 550°C, other optimized 200 
parameters were: ionspray voltage (IS), -4.2 kV; gas source 1 (GS1), 55 psi; gas source 201 
2 (GS2), 55 psi; curtain gas (CUR), 35 psi. MS–MS product ions were produced by 202 
collisional induced dissociation (CID) of selected precursor ions in the LINAC collision 203 
cell (Q2) and mass-analyzed in the second mass filter (Q3). Nitrogen was used as 204 
collision gas (CAD) at 8 mPa pressure. Additional experimental conditions for MS–MS 205 
product ions spectra are reported in Table 1. 206 
 207 
*** Table 1 here *** 208 
 209 
 210 
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2.5 Method validation 211 
 212 
Calibration curves were obtained by plotting the analytes to IS peak areas ratios versus 213 
analytes to IS nominal concentrations ratios. The ratios of the peak area of the analytes 214 
to IS were corrected for the presence of endogenous compounds in the matrix, by 215 
subtracting the corresponding ratios of the blank. The concentrations of the analytes in 216 
unknown and QC samples were obtained multiplying the known IS concentration by the 217 
ratio of analyte to IS concentrations provided by the calibration curve. All calculations 218 
were performed in EXCEL® software (Microsoft Corporation, USA) using the function 219 
formulas for mean (―average‖) and standard deviation (―stdev‖). The limit of detection 220 
(LOD) and limit of quantitation (LOQ) were determined from the slope (S) and the 221 
standard deviation of the intercept (y) of matrix based calibration curve, according to 222 
the formulas  LOD = 3   (y/S) ; LOQ = 10   (y/S) [21]. 223 
Intra-day accuracy and precision were evaluated from replicate analyses (five runs, five 224 
replicates per run) of QC samples at three different final concentrations (15, 150, 450 225 
ng/mL) carried out in the same day. QC working solutions were pre-spiked to aliquots 226 
of the urine pool used as reference matrix. Inter-day accuracy and precision were 227 
assessed from the same sets of QC samples in five different days.  228 
Precision was expressed as coefficient of variation (CV%) and calculated using the 229 
formula: CV% = (standard deviation/mean) × 100%.  230 
Accuracy is the degree of closeness of the determined values to the nominal, and it was 231 
expressed as percentage of the measured versus the nominal concentration.  232 
Absolute and extraction recoveries were expressed as percentage calculated comparing 233 
the peak areas of the QC pre-spiked samples (Aqc-pre) with the peak areas of the QC 234 
standard solutions (Astd) for absolute recovery (REabs (%) = 100   Aqc-pre / Astd), and 235 
with the peak area of QC post-spiked samples (Aqc-post) for extraction recovery (REext 236 
(%) = 100   Aqc-pre / Aqc-post), respectively.                              237 
 10 
Reduction of matrix effect by dilution was evaluated and calculated according to the 238 
method described by Kruve et al. [22]. An aliquot of the pool of urine was extracted by 239 
SPE and then spiked with a standards solution to provide a final concentration of 450 240 
ng/mL for all the analytes. The eluate and the reference standards solution (450 ng/mL) 241 
were analyzed at their initial concentration and after dilution from 1 to 2 to 1 to 100 242 
with a MeOH-H2O (50:50, v/v) mixture. A dilution factor of 0.5 (see section 3 for 243 
details) for the eluate coming from the SPE was then used to evaluate the matrix effect 244 
(ME) as percentage comparing the peak areas of the QC post-spiked samples with the 245 
peak areas of the QC samples prepared in neat solution (ME (%) = 100   Aqc-post / Astd) 246 
 247 
2.6 Preliminary study on PCOS samples 248 
24 h urine samples coming from healthy volunteers (n = 25 female, age 19-49) and from 249 
PCOS patients (n = 12 female, age 18-37) were analyzed using the validated method 250 
here described for the determination of the level of free and total E, F, THE, THF and 251 
A-THF.  252 
 253 
3. Results and Discussion 254 
3.1 LC-MS/MS analytical method development 255 
As already reported in our previous paper [16] on the determination of the free fraction 256 
of glucocorticoids, negative ion mode Electrospray Ionization (ESI) provides very high 257 
sensitivity and specificity for the determination of cortisol and its metabolites [23]. 258 
Under our experimental conditions, fragmentation of [M+HCOO]
-
 adduct provided [M-259 
CH2O-H]
-
 as the most abundant ion for all the compounds examined [16]. This 260 
transition was selected  for quantification of the five glucocorticoids and internal 261 
standard, Fd4, in SRM mode. 262 
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In order to further increase the ESI sensitivity, we moved from the 50 × 4.6 mm [16]  to 263 
the 50 × 2.1 mm Restek Allure Biphenyl column. Isobaric endogenous compounds were 264 
detected in the SRM transition profile of A-THF and F coming from urine samples 265 
analysis, not present in standards mixtures and co-eluting with the two analytes using 266 
the 4.6 mm i.d. column. Thus, elution conditions were carefully tuned in terms of 267 
mobile phase composition and ramp, flow rate, injection volume and column 268 
temperature (see Experimental Section for details), leading to the baseline separation of 269 
the two stereoisomers THF and A-THF, besides the other compounds under study.  270 
Comparing the data coming from the previous and new developed method on a set of 271 
control urines, we found that the final improved chromatographic conditions avoided an 272 
overestimation of the amount of A-THF and F by 10-15% on average, in some cases 273 
reaching 30-40% for F.  274 
LC-MS/MS ionization parameters were then optimized for strongest product ion signal 275 
intensities, following the transitions reported in Table 1.  276 
We used Fd4 in place of methyl-prednisolone as internal standard as it provided an 277 
accuracy increase by 10-15% in the determination of F and its metabolites, without 278 
substantially affecting the determination accuracy for E and THE. Deuterated cortisol 279 
was easily prepared in our lab at low cost in few simple steps starting form cortisone 280 
[19]. In Fig. 2, a representative chromatogram of the separation of the five components 281 
of an urine sample is reported. 282 
 283 
*** Figure 2 here *** 284 
Fig. 2. Typical LC-MS/MS chromatographic profiles for the determination of cortisol 285 
and its metabolites in an urine sample. The chromatographic traces for the MS/MS 286 
transition of each compound (see Table 1 for conditions) are superimposed. It is worth 287 
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notice the separation of THF from A-THF peak, as the two compounds share the same 288 
transition. 289 
 290 
3.2 Enzymatic hydrolysis 291 
We wanted to determine not only the five urinary free glucocorticoids but also their 292 
total amount, to have a complete overview of the analytes profile. As glucocorticoids 293 
are present in urine largely as conjugates derivatives (about 95% glucuronides and 3-4% 294 
sulfates), their total amount in urine is generally determined after enzymatic 295 
deconjugation. In that regard, one of the most used enzymes mixture is the Helix 296 
pomatia type H-1 juice, which is characterized by glucuronidase and arylsulfatase 297 
activities. As different deconjugation conditions were described in literature [24,25], we 298 
carried out a series of experiments to find the best procedure for our purposes.  299 
We set the temperature of the enzymatic hydrolysis at 55°C, as lower temperatures (37-300 
40°C) were reported to require very long incubation time (24–48 h) [26]. Hydrolysis 301 
experiments of urine samples were carried out varying the concentration of the enzyme 302 
and the incubation time. Differently from previously reported data [27], we observed 303 
that an enzyme concentration of 1.4 U/mL was not adequate to achieve complete 304 
hydrolysis of the analytes conjugates after 4 h of incubation time at 55°C, in particular 305 
as regard A-THF. Plateau levels of the five glucocorticoids were reached increasing the 306 
Helix Pomatia concentration up to 5.4 U/mL over 4 h of incubation. Thus, those 307 
conditions were employed to determine the total amount of E, F, THE, THF and A-THF 308 
in urine samples. 309 
 310 
 311 
3.3 Sample preparation  312 
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We used Oasis HLB cartridges for the SPE extraction of the five analytes, as they 313 
proved to be very efficient in terms of recovery and reproducibility in the extraction of 314 
cortisol and its metabolites from urine [16,17]. The amount of urine sample required for 315 
the analysis of the free and total glucocorticoids was investigated. For the determination 316 
of free glucocorticoids, urine volumes below two milliliters afforded the accurate 317 
determination of E and F and THE, but not of THF and A-THF. Thus, washing and 318 
elution conditions were optimized on a two milliliters urine loading. For the 319 
determination of total glucocorticoids, the volumes of 500, 250 and 125 L of urine 320 
were investigated. The latter resulted adequate for the detection of the studied analytes 321 
after the enzymatic hydrolysis and the appropriate dilution to avoid signal saturation.  322 
Samples were always analyzed as MeOH-H2O (50:50, v/v) solvent mixture, that 323 
practically are the starting elution conditions of the analytical method, as alterations of 324 
the chromatographic performances were observed for some compounds when injecting 325 
samples in pure methanol. 326 
 327 
3.4 Calibration curves, matrix effect and recoveries 328 
Calibration curves should be prepared in the same blank matrix as the samples. For this 329 
purpose, different blank urine samples have been reported in literature. Steroid free 330 
urine matrices were generally obtained by removing the endogenous steroids by 331 
treatment with sorbents (i.e. activated carbon [28]). In some cases, a mixture of water 332 
and salts and other components contained in urine (like NaCl, KCl, CaCl2, urea and 333 
phosphates) was used as synthetic urine free of steroids [29]. We explored all those 334 
options and compared them with the calibration curve constructed using MeOH-H2O as 335 
solvent. The steroid free matrices were extracted according to the developed SPE 336 
protocol and then spiked with specified amounts of standard solution to cover the 0.5-337 
1000 ng/mL concentration range. The slope of the calibration curve built with neat 338 
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solvent, synthetic urine and urine treated with activated carbon resulted almost the 339 
same, suggesting the substantial absence of matrix effects. However, to verify how 340 
close those matrices mimed real samples, we also constructed a calibration curve by 341 
spiking urine aliquots, coming from a pool of healthy volunteers 24 h urines, with 342 
standard solutions in the same range of the concentrations used before. The slope of the 343 
latter curves for E and, in a lesser extent, for THE, proved to be different from those 344 
obtained using steroid free matrices, indicating the presence of a matrix effect for these 345 
two compounds. Thus, in our hands, the steroid free matrices proved to be not adequate 346 
for the accurate determination of E and THE, differently from what reported elsewhere 347 
[17,29]. 348 
We then investigated if sample dilution could reduce or eliminate the matrix effects, 349 
following the approach employed recently by Kruve et al. [22]. According to this 350 
approach, reduction or elimination of matrix effects upon dilution are evaluated through 351 
the comparison of the calculated concentrations of undiluted and diluted samples. 352 
In our case, we spiked a sample of the pool of urine extracted by SPE and investigated 353 
dilution factors from 1 to 0.01. As expected, A-THF, THF and F were slightly affected 354 
by dilution, showing the substantial elimination of the matrix effect just with a 0.5 355 
dilution factor. Dilution 1 to 5 was necessary for THE to achieve the same result, while 356 
E concentration reached the plateau using a dilution factor of 0.1 (see Fig. 3). However, 357 
the latter could not be used for our purposes, as free THF and A-THF are present in 358 
urine in low amounts. Hence, matrix based calibration curves had to be used to 359 
minimize inaccuracy in the determination of THE and E. From a set of experiments 360 
carried out on several urine matrices, we eventually chose to employ a 0.5 dilution 361 
factor for the eluate coming from SPE, in order to further avoid possible inaccuracy in 362 
the determination of free forms. In fact, in that way we verified the complete 363 
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elimination of the small fluctuations in quantification observed using some matrices, 364 
maintaining the required level of sensitivity. 365 
For the determination of the total amount of the five glucocorticoids, the calibration 366 
curve built in MeOH-H2O was used for calculations, as the eluates coming from the 367 
SPE of the hydrolyzed samples were diluted 1 to 20 to fit their concentrations into the 368 
dynamic range of the calibration curve. In that case, the matrix effect is eliminated for 369 
all the components under study using such dilution, as described above.  370 
 371 
*** Figure 3 here *** 372 
 373 
Fig. 3. Dilution plot of E. Plateau level for the concentration of E was obtained using a 374 
0.1 or less dilution factor, indicating that a ten-fold or more dilution is necessary to 375 
eliminate the matrix effects for E. 376 
 377 
On the basis of the obtained results, the post-extraction spiked method [30] was 378 
employed to assess the matrix effect as percentage using a dilution 1 to 2 of the eluate 379 
coming from the SPE. Matrix effect values (ME) are reported in Table 2. A value equal 380 
to 100% indicates the absence of matrix effect, while values over or less than 100% 381 
indicates an ionization enhancement or suppression, respectively. 382 
 383 
*** Table 2 here *** 384 
 385 
The extraction recoveries resulted close to 100% (Table 2) for all the glucocorticoids 386 
examined at the three QC concentrations tested (15, 150, 450 ng/mL), in a reproducible 387 
way, indicating that the SPE protocol developed was very efficient. As regard the 388 
absolute recoveries (Table 2), almost the same results were obtained for F, A-THF and 389 
THF, while E and THE provided values lower than 100%, 71 and 85% in the worst case 390 
respectively, because of matrix effect resulting in signal suppression.  391 
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3.5 Linearity, limit of detection, precision and accuracy 392 
The linearity of the method was evaluated by analyzing calibration standards of the five 393 
analytes in the range 0.5-1000 ng/mL, both in neat solution and in the presence of 394 
matrix. The range of linearity for each analyte for solvent and matrix based calibration 395 
curves are reported in Table 3. Solvent based curves were used for the determination of 396 
the amount of unconjugated plus conjugated glucocorticoids, as described above. The 397 
resulting correlation coefficients were very good, ranging from 0.9981 to 0.9995. 398 
Regarding E and THE, the linear range of solvent and matrix based calibration curves 399 
reflected the matrix effect observed in the determination of these two compounds. In 400 
fact, signal saturation for THE and E was obtained over 600 ng/mL for the solvent 401 
based calibration curve, while over 900 ng/mL for the matrix based calibration curve, 402 
indicating the suppression of the response due to the matrix effect. The effect influenced 403 
also the lower limit of detection and quantitation, that were higher for the matrix based 404 
curve compared to the standards solution curve, as expected. Limit of detection (LOD) 405 
and limit of quantitation (LOQ), reported in Table 3, were determined according to ICH 406 
(International Conference on Harmonization) guideline [31] from the slope (S) and the 407 
standard deviation of the intercept (y) of the calibration curve.  408 
 409 
*** New Table 3 here *** 410 
 411 
 412 
Precision and accuracy were evaluated using QC samples pre-spiked in urine aliquots at 413 
three different concentrations (15, 150, 450 ng/mL). As reported in Table 4, intra and 414 
inter-day precision were 0.4–7.7% and 1.1–10% respectively, thus more than acceptable 415 
for the validation of the method. In that regard, also the accuracy data were pretty good, 416 
ranging from 90 to 109%.  417 
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 418 
*** Table 4 here *** 419 
 420 
3.6. Preliminary study on PCOS urine samples 421 
The validated reported protocol was employed in a preliminary study within our project 422 
regarding the possible relationship of urinary glucocorticoids to PCOS condition and 423 
other pathologies related to cortisol metabolism. Since conjugation is mainly a hepatic 424 
process, the ratio of total urinary tetrahydrometabolites of cortisol and cortisone (A-425 
THF + THF/THE ratio) gives information on the activity of hepatic 11-HSD1, while 426 
the ratio of urinary free F and E provides an index of activity of 11-HSD2 [2]. In 427 
addition, the urinary A-THF/THF ratio can give information about the global activity of 428 
5-reductase [10]. Thus, the amount of the five analytes and the ratios related to the 429 
activity of 5-reductase, 11-HSD1 and 2 were determined both for the free and total 430 
forms in 24 h urine samples coming from healthy subjects and PCOS patients.  431 
In agreement with previously published data [5,32], both free and total A-THF/THF 432 
ratio were higher than in control subjects, while A-THF + THF/THE ratio of total forms 433 
showed no significant differences between PCOS patients and controls (Table 5). As 434 
expected [11], free forms are present in very low amount compared to the total 435 
fractions, in particular for the tetrahydro metabolites (i.e. free A-THF is present about 436 
two thousands-fold lower than total A-THF form). 437 
Conversely, a possible alteration of 11-HSD1 and 11-HSD2 activity was observed, as 438 
the free F/E and A-THF + THF/THE ratios were lower than in control subjects 439 
(P<0.01). That finding is particularly interesting and will be further investigated on a 440 
larger number of patients in the next future, as for the time being, the alteration of 441 
11HSD1 activity could be detected only using total A-THF + THF + cortol/THE + 442 
cortolones ratio as marker [5,32].  443 
 18 
*** Table 5 here *** 444 
 445 
 446 
4. Conclusions 447 
A solid phase extraction LC–MS/MS bio-analytical method was developed and 448 
validated with a thorough study for the quantification of free and free plus conjugated 449 
cortisol, cortisone and their metabolites in human urine. The chromatographic method 450 
allowed the baseline separation of all the compounds under study, in particular the 451 
separation of the two stereoisomers A-THF and THF from the isobaric endogenous 452 
unknown compounds interfering with their determination, thus avoiding overestimation. 453 
Validated range for all the compounds, LOD, LOQ, intra and inter-day precision and  454 
accuracy meet the suggested industry and regulatory acceptance criteria. The resulting 455 
extraction and absolute recoveries proved to be very satisfactory and reproducible, 456 
showing the ruggedness of the procedure. 457 
The study of matrix effects showed that free steroids urines used as matrix in several 458 
methods are not adequate for accurate determination of E and THE, that hence requires 459 
matrix based calibration curves.  460 
The validated procedure was successfully applied in a preliminary investigation carried 461 
out to profile the five analytes in urine samples of PCOS patients. The data obtained 462 
support the hypothesis that the determination of both urinary free and total 463 
glucocorticoids can provide precious information and new perspectives in the diagnosis 464 
of pathological conditions related to the alteration of cortisol metabolism.  465 
 466 
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Table 1. Experimental MS conditions for analytes determination. 
a
DP = Declustering Potential; EP = Entrance Potencial; CE = Collision Energy; CXP = Cell Exit Potential 
 Transition Ion (m/z) DP
a 
EP
a 
CE
a 
CXP
a 
F 407-331 -50 -8 -25 -8 
E 405-329 -50 -10 -20 -8 
THF-ATHF 411-335 -50 -8 -25 -8 
THE 409-333 -45 -6 -25 -4 
Fd4 411-335 -50 -10 -25 -10 
Table 1
 Table 2. Recoveries and matrix effect of each analyte (n. of replicates = 5) 
 
 QC Conc. 
(ng/mL) 
REext 
 (%, ±SD) 
REabs 
 (%, ±SD) 
ME  
(%, ±SD) 
ATHF 15 109±5 101±5 96±3 
 150 105±6 99±6 102±2 
 450 99±6 99±6 103±6 
E 15 99±2 71±5 65±7 
 150 102±2 74±4 70±6 
 450 102±3 77±5 72±5 
F 15 101±3 97±3 93±7 
 150 103±3 102±3 96±9 
 450 101±2 98±2 97±1 
THE 15 104±1 88±4 90±7 
 150 103±2 90±5 87±4 
 450 100±3 85±3 84±6 
THF 15 112±3 106±3 94±4 
 150 105±2 97±4 95±7 
 450 100±4 100±4 102±7 
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Table 3. Solvent and matrix based calibration curves parameters. 
 
 
 
 
 
 
 
Solvent based calibration curves 
 Slope Intercept R
2
 Calibration 
range (ng/mL) 
LOD  
(ng/mL) 
LOQ  
(ng/mL) 
A-THF
 
0.13 0.002 0.9994 0.5-1000 0.05 0.15 
E
 
3.01 0.047 0.9981 0.5-500 0.2 0.6 
F
 
1.75 0.241 0.9990 1-1000 0.1 0.3 
THE
 
0.89 0.051 0.9960 0.5-500 0.1 0.3 
THF
 
0.31 -0.014 0.9995 0.5-1000 0.05 0.15 
       
Matrix based calibration curves 
 Slope Intercept R
2
 Calibration 
range (ng/mL) 
LOD  
(ng/mL) 
LOQ  
(ng/mL) 
A-THF
 
0.12 -0.006 0.9994 0.5-1000 0.1 0.3 
E
 
1.22 0.969 0.9940 5-800 1 3 
F
 
1.73 0.229 0.9990 1-1000 0.2 0.6 
THE
 
0.58 0.237 0.9890 5-800 0.2 0.6 
THF
 
0.29 -0.007 0.9993 0.5-1000 0.1 0.3 
Table 3
 Table 4. Intra-day and inter-day precision and accuracy of QC analytes determination (five 
runs, five replicates per run). 
 
                                                                Precision 
 
QC Conc. 
(ng/mL) 
Accuracy 
(%)  
Intra-day 
(CV%) 
Inter-day 
 (CV%) 
ATHF 15 100 0.8 2.4 
 150 90 2 2.2 
 450 90 2.5 3.5 
E 15 105 0.8 1.8 
 150 107 3.2 4.7 
 450 97 2.8 9.6 
F 15 101 0.8 2.8 
 150 105 0.9 1.8 
 450 95 0.4 1.8 
THE 15 102 0.8 1.1 
 150 109 0.9 1.3 
 450 101 0.5 7.3 
THF 15 109 1 1.3 
 150 101 0.8 1.5 
 450 94 1.2 1.9 
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 Table 5. Concentration and relative ratios of free and total urinary corticoids in control subjects and 
patients with PCOS. 
 

Free Glucocorticoids 
(g/day urine) 
Total Glucocorticoids 
(mg/day urine) 
Controls PCOS Controls PCOS 
 
n = 25 
(19-49 years) 
n =12 
(18-37 years) 
 n = 25 
(19-49 years) 
n =12 
(18-37 years) 
F 24.00 ± 1.10 6.52 ± 0.24 0.11 ± 0.01 0.11 ± 0.01 
E 42.20 ± 2.05 23.14 ± 0.11 0.22 ± 0.01 0.23 ± 0.01 
THF 8.99 ± 0.35 3.74 ± 0.21 2.70 ± 0.12 1.80 ± 0.06 
A-THF 0.77 ± 0.02 0.52 ± 0.02 1.93 ± 0.12 1.57 ± 0.05 
THE 10.04 ± 0.61 11.71 ± 0.72 4.07 ± 0.22 4.60 ± 0.18 
     
THF+A-THF/THE 0.97 ± 0.10 0.61 ± 0.04 1.10 ± 0.12 0.83 ± 0.05 
A-THF/THF 0.08 ± 0.01 0.17 ± 0.01 0.65 ± 0.07 0.90 ± 0.06 
F/E 0.57 ± 0.05 0.30 ± 0.01 0.54 ± 0.06 0.51 ± 0.05 
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